Effect of cationic lipid type in PEGylated liposomes on siRNA delivery following the intravenous injection of siRNA lipoplexes

Hattori,Yoshiyuki; Nakamura,Mari; Takeuchi,Nozomi; Tamaki,Kyoko; Ozaki,Kei‑Ichi; Onishi,Hiraku

doi:10.3892/wasj.2019.8

Effect of cationic lipid type in PEGylated liposomes on siRNA delivery following the intravenous injection of siRNA lipoplexes

Authors:
- Yoshiyuki Hattori
- Mari Nakamura
- Nozomi Takeuchi
- Kyoko Tamaki
- Kei‑Ichi Ozaki
- Hiraku Onishi
View Affiliations

Affiliations: Department of Drug Delivery Research, Hoshi University, Tokyo 142‑8501, Japan, Education and Research Center for Pharmaceutical Sciences, Osaka University of Pharmaceutical Sciences, Takatsuki, Osaka 569‑1094, Japan
Published online on: March 29, 2019 https://doi.org/10.3892/wasj.2019.8
Pages: 74-85
Copyright: © Hattori et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

For the systemic injection of cationic liposome/small interfering RNA (siRNA) complexes (cationic lipoplexes), the polyethylene glycol (PEG)‑modification (PEGylation) of the lipoplexes can enhance their systemic stability. However, PEGylation reduces the efficiency of siRNA‑mediated gene silencing by cationic lipoplexes. In this study, in order to examine the effects of cationic lipids in PEGylated liposomes on gene‑silencing effects following the systemic injection of PEGylated lipoplexes, we used 4 types of cationic cholesterol derivatives and 3 types of dialkyl or trialkyl cationic lipids, and prepared 7 types of PEGylated cationic lipoplexes that contained 1 mol% PEG2000‑DSPE. The PEGylation of lipoplexes decreased their agglutination with erythrocytes. As regards siRNA biodistribution and the in vivo gene‑silencing effects, intravenous injections of PEGylated lipoplexes with cationic cholesterol derivatives induced the accumulation of siRNAs in the liver, but they did not suppress the expression of a target gene. By contrast, those with dialkyl or trialkyl cationic lipids induced the accumulation of siRNAs in the lungs, and among these, PEGylated cationic lipoplexes with N,N‑dimethyl‑N‑octadecyloctadecan‑1‑aminium bromide (DC‑1‑18) significantly induced gene silencing effects in the lungs. On the whole, the findings of this study suggest that the biodistribution and gene silencing effects with siRNAs following the systemic injection of 1 mol% PEGylated lipoplexes are strongly affected by the type of cationic lipid. The selection of the cationic lipid in the liposomal formulation may thus be important for the successful in vivo delivery of siRNAs by PEGylated cationic liposomes.

View Figures

View References

1	Wilson RC and Doudna JA: Molecular mechanisms of RNA interference. Annu Rev Biophys. 42:217–239. 2013.PubMed/NCBI View Article : Google Scholar
2	Bumcrot D, Manoharan M, Koteliansky V and Sah DW: RNAi therapeutics: A potential new class of pharmaceutical drugs. Nat Chem Biol. 2:711–719. 2006.PubMed/NCBI View Article : Google Scholar
3	Castanotto D and Rossi JJ: The promises and pitfalls of RNA-interference-based therapeutics. Nature. 457:426–433. 2009.PubMed/NCBI View Article : Google Scholar
4	Hickerson RP, Vlassov AV, Wang Q, Leake D, Ilves H, Gonzalez-Gonzalez E, Contag CH, Johnston BH and Kaspar RL: Stability study of unmodified siRNA and relevance to clinical use. Oligonucleotides. 18:345–354. 2008.PubMed/NCBI View Article : Google Scholar
5	Wang J, Lu Z, Wientjes MG and Au JL: Delivery of siRNA therapeutics: Barriers and carriers. AAPS J. 12:492–503. 2010.PubMed/NCBI View Article : Google Scholar
6	Chen X, Mangala LS, Rodriguez-Aguayo C, Kong X, Lopez-Berestein G and Sood AK: RNA interference-based therapy and its delivery systems. Cancer Metastasis Rev. 37:107–124. 2018.PubMed/NCBI View Article : Google Scholar
7	de Fougerolles AR: Delivery vehicles for small interfering RNA in vivo. Hum Gene Ther. 19:125–132. 2008.PubMed/NCBI View Article : Google Scholar
8	Zhang S, Zhi D and Huang L: Lipid-based vectors for siRNA delivery. J Drug Target. 20:724–735. 2012.PubMed/NCBI View Article : Google Scholar
9	Zhang Y, Satterlee A and Huang L: In vivo gene delivery by nonviral vectors: Overcoming hurdles? Mol Ther. 20:1298–1304. 2012.PubMed/NCBI View Article : Google Scholar
10	Xia Y, Tian J and Chen X: Effect of surface properties on liposomal siRNA delivery. Biomaterials. 79:56–68. 2016.PubMed/NCBI View Article : Google Scholar
11	Hatakeyama H, Akita H and Harashima H: The polyethyleneglycol dilemma: Advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors. Biol Pharm Bull. 36:892–899. 2013.PubMed/NCBI View Article : Google Scholar
12	Lee J and Ahn HJ: PEGylated DC-Chol/DOPE cationic liposomes containing KSP siRNA as a systemic siRNA delivery Carrier for ovarian cancer therapy. Biochem Biophys Res Commun. 503:1716–1722. 2018.PubMed/NCBI View Article : Google Scholar
13	Zhang Y, Li H, Sun J, Gao J, Liu W, Li B, Guo Y and Chen J: DC-Chol/DOPE cationic liposomes: A comparative study of the influence factors on plasmid pDNA and siRNA gene delivery. Int J Pharm. 390:198–207. 2010.PubMed/NCBI View Article : Google Scholar
14	Hattori Y, Machida Y, Honda M, Takeuchi N, Yoshiike Y, Ohno H and Onishi H: Small interfering RNA delivery into the liver by cationic cholesterol derivative-based liposomes. J Liposome Res. 27:264–273. 2017.PubMed/NCBI View Article : Google Scholar
15	Santel A, Aleku M, Keil O, Endruschat J, Esche V, Fisch G, Dames S, Löffler K, Fechtner M, Arnold W, et al: A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther. 13:1222–1234. 2006.PubMed/NCBI View Article : Google Scholar
16	Fehring V, Schaeper U, Ahrens K, Santel A, Keil O, Eisermann M, Giese K and Kaufmann J: Delivery of therapeutic siRNA to the lung endothelium via novel Lipoplex formulation DACC. Mol Ther. 22:811–820. 2014.PubMed/NCBI View Article : Google Scholar
17	Hattori Y, Hara E, Shingu Y, Minamiguchi D, Nakamura A, Arai S, Ohno H, Kawano K, Fujii N and Yonemochi E: siRNA delivery into tumor cells by cationic cholesterol derivative-based nanoparticles and liposomes. Biol Pharm Bull. 38:30–38. 2015.PubMed/NCBI View Article : Google Scholar
18	Ding W, Hattori Y, Higashiyama K and Maitani Y: Hydroxyethylated cationic cholesterol derivatives in liposome vectors promote gene expression in the lung. Int J Pharm. 354:196–203. 2008.PubMed/NCBI View Article : Google Scholar
19	Hattori Y, Nakamura T, Ohno H, Fujii N and Maitani Y: siRNA delivery into tumor cells by lipid-based nanoparticles composed of hydroxyethylated cholesteryl triamine. Int J Pharm. 443:221–229. 2013.PubMed/NCBI View Article : Google Scholar
20	Hattori Y, Arai S, Kikuchi T, Ozaki KI, Kawano K and Yonemochi E: Therapeutic effect for liver-metastasized tumor by sequential intravenous injection of anionic polymer and cationic lipoplex of siRNA. J Drug Target. 24:309–317. 2016.PubMed/NCBI View Article : Google Scholar
21	Hattori Y, Arai S, Okamoto R, Hamada M, Kawano K and Yonemochi E: Sequential intravenous injection of anionic polymer and cationic lipoplex of siRNA could effectively deliver siRNA to the liver. Int J Pharm. 476:289–298. 2014.PubMed/NCBI View Article : Google Scholar
22	Aleku M, Schulz P, Keil O, Santel A, Schaeper U, Dieckhoff B, Janke O, Endruschat J, Durieux B, Röder N, et al: Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res. 68:9788–9798. 2008.PubMed/NCBI View Article : Google Scholar
23	Hattori Y, Nakamura A, Arai S, Kawano K, Maitani Y and Yonemochi E: siRNA delivery to lung-metastasized tumor by systemic injection with cationic liposomes. J Liposome Res. 25:279–286. 2015.PubMed/NCBI View Article : Google Scholar
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
25	Hattori Y, Nakamura M, Takeuchi N, Tamaki K, Shimizu S, Yoshiike Y, Taguchi M, Ohno H, Ozaki KI and Onishi H: Effect of cationic lipid in cationic liposomes on siRNA delivery into the lung by intravenous injection of cationic lipoplex. J Drug Target. 27:217–227. 2019.PubMed/NCBI View Article : Google Scholar
26	Hattori Y, Takeuchi N, Nakamura M, Yoshiike Y, Taguchi M, Ohno H, Ozaki K and Onishi H: Effect of cationic lipid type in cationic liposomes for siRNA delivery into the liver by sequential injection of chondroitin sulfate and cationic lipoplex. J Drug Deliv Sci Technol. 48:235–244. 2018. View Article : Google Scholar
27	Yoshikawa N, Fumoto S, Nakashima M, Shimokawa K, Miyamoto H and Nishida K: The role of fibronectin in pulmonary gene transfer following intravenous administration of lipoplex in mice. Biol Pharm Bull. 36:1807–1813. 2013.PubMed/NCBI View Article : Google Scholar
28	Simberg D, Weisman S, Talmon Y, Faerman A, Shoshani T and Barenholz Y: The role of organ vascularization and lipoplex-serum initial contact in intravenous murine lipofection. J Biol Chem. 278:39858–39865. 2003.PubMed/NCBI View Article : Google Scholar